VITALITY Study Demonstrates the Long-Term Durability of Patient Outcomes In Treating Symptomatic Uterine Fibroids Redwood City, CA – March 5, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas) today announced the publication of the VITALITY study in the Journal […]
Robust Outcomes Support the Potential of the Sonata System as a First-Line Treatment for Symptomatic Uterine Fibroids Redwood City, CA – January 10, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas) today announced the publication of the SONATA IDE […]
Equity Round led by Bain Capital Life Sciences Redwood City, CA – January 3, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata System and other advanced, incision-free solutions for the treatment of uterine conditions, today announced that it has completed a $75 million equity financing. The financing was led by […]
Impressive 12-Month Patient Outcomes from SONATA Pivotal IDE Trial Being Highlighted Redwood City, CA – Nov 12, 2018 – Gynesonics, a women’s healthcare company focused on the development of advanced minimally invasive solutions for the treatment of uterine conditions, today announced that its Sonata® System for transcervical treatment of uterine fibroids will be featured in […]
Advanced technology offers potential to become a new standard of care for fibroid treatment Redwood City, CA – August 22, 2018 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to […]
Results highlight robust Sonata System design and its potential to become a standard of care for fibroid treatment Redwood City, CA – January 9, 2018 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the results from their pivotal IDE trial for the Sonata® […]
Novel uterus-preserving Sonata System is first incision-free treatment to address majority of fibroids transcervically Redwood City, CA – December 21, 2017 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for uterine fibroids, today announced its submission to the FDA of its 510(k) Premarket Notification for the Sonata® System, a […]
Respected Leader in Medical Device Manufacturing and Engineering Management Redwood City, CA – March 30, 2017 – Gynesonics, a women’s healthcare company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of symptomatic uterine fibroids, today announced that medical device executive James Sparks has been named Vice President […]
First Health Economic Outcomes Research with Sonata Treatment to be Presented Redwood City, CA – Nov 10, 2016 – Gynesonics, a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions, today announced that its Sonata® System technology platform for transcervical incision-free treatment of uterine fibroids will be […]
Increasing Body of Evidence Further Demonstrates Compelling Outcomes Redwood City, CA – October 19, 2016 – Gynesonics, a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions, today announced that its Sonata® System technology platform for transcervical incision-free treatment of uterine fibroids will be featured in three […]
